Annotation Detail

Information
Associated Genes
NRAS
Associated Variants
NRAS MUTATION
NRAS MUTATION
Associated Disease
skin melanoma
Source Database
CIViC Evidence
Description
NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/2937
Gene URL
https://civic.genome.wustl.edu/links/genes/36
Variant URL
https://civic.genome.wustl.edu/links/variants/208
Rating
5
Evidence Type
Predictive
Disease
Skin Melanoma
Evidence Direction
Supports
Drug
Binimetinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
28284557
Drugs
Drug NameSensitivitySupported
BinimetinibSensitivitytrue